Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stratification of obesity phenotypes to optimize future therapy (SOPHIA).
Tahrani AA, Panova-Noeva M, Schloot NC, Hennige AM, Soderberg J, Nadglowski J, Tarasenko L, Ahmad NN, Sleypen BS, Bravo R, Al-Najim W, le Roux CW. Tahrani AA, et al. Among authors: le roux cw. Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(10):1031-1039. doi: 10.1080/17474124.2023.2264783. Epub 2023 Oct 24. Expert Rev Gastroenterol Hepatol. 2023. PMID: 37791820 Review.
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
Papamargaritis D, Al-Najim W, Lim J, Crane J, Lean M, le Roux C, McGowan B, O'Shea D, Webb D, Wilding J, Davies MJ. Papamargaritis D, et al. BMJ Open. 2020 Feb 13;10(2):e034137. doi: 10.1136/bmjopen-2019-034137. BMJ Open. 2020. PMID: 32060156 Free PMC article.
Food preferences after bariatric surgery: a review update.
Alabduljabbar K, Al-Najim W, le Roux CW. Alabduljabbar K, et al. Among authors: le roux cw. Intern Emerg Med. 2023 Mar;18(2):351-358. doi: 10.1007/s11739-022-03157-9. Epub 2022 Dec 7. Intern Emerg Med. 2023. PMID: 36478323 Review.
The double burden: Navigating type 1 diabetes and obesity.
Steenackers N, Feldman AN, Mathieu C, Rosen J, Soderberg J, Al-Ozairi E, le Roux CW, Van der Schueren B. Steenackers N, et al. Among authors: le roux cw. Clin Obes. 2024 Jun;14(3):e12645. doi: 10.1111/cob.12645. Epub 2024 Feb 9. Clin Obes. 2024. PMID: 38334191 No abstract available.
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).
Al-Ozairi E, Narula K, Miras AD, Taghadom E, Samad AE, Al Kandari J, Alyosef A, Mashankar A, Al-Najim W, le Roux CW. Al-Ozairi E, et al. Among authors: le roux cw. Trials. 2024 Feb 16;25(1):129. doi: 10.1186/s13063-024-07930-3. Trials. 2024. PMID: 38365744 Free PMC article.
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Jastreboff AM, et al. Among authors: le roux cw. N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819. Online ahead of print. N Engl J Med. 2024. PMID: 39536238
469 results